AgomAb Therapeutics NV American Depositary Shares (AGMB) Financials
Key financial figures for AgomAb Therapeutics NV American Depositary Shares (Q4 2025), as reported in EUR.
AgomAb Therapeutics N.V. reported revenue of 0.00 EUR for Q4 FY2025. The company posted a net loss of 17.4 million EUR, or -0.36 EUR per share. Free cash flow for the period was -13.2 million EUR. The figures above are as filed, and the full income statement, balance sheet and cash flow history for AgomAb Therapeutics N.V. are on the SentiSense financials page.
- Revenue
- EUR 0
- Net Income
- -EUR 17M
- EPS
- EUR -0.36
- Total Assets
- EUR 154M
- Operating Cash Flow
- -EUR 13M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q4 FY2025 | EUR 0 | -EUR 17M | -EUR 0.36 | -EUR 13M | |
| Q3 FY2025 | EUR 0 | -EUR 18M | -EUR 0.43 | -EUR 14M | |
| Q4 FY2024 | EUR 0 | -EUR 12M | -EUR 0.32 | -EUR 13M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | EUR 0 | -EUR 63M | -EUR 1.28 | -EUR 52M | |
| FY2024 | EUR 0 | -EUR 46M | -EUR 1.26 | ||
| FY2023 | EUR 0 | -EUR 11M | -EUR 0.31 |
Frequently asked questions
What was AgomAb Therapeutics N.V.'s revenue last quarter?
AgomAb Therapeutics N.V. reported revenue of 0.00 EUR for Q4 FY2025.
Is AgomAb Therapeutics N.V. profitable?
Not in its most recent reported period. AgomAb Therapeutics N.V. reported a net loss of 17.4 million EUR for Q4 FY2025.
How much free cash flow did AgomAb Therapeutics N.V. generate?
AgomAb Therapeutics N.V. generated free cash flow of -13.2 million EUR in Q4 FY2025, after capital expenditure.
Figures are as reported by the filer in EUR and are not converted to US dollars. The share price is quoted in US dollars, so the two are not directly comparable.
Full income statement, balance sheet and cash flow for AgomAb Therapeutics NV American Depositary Shares on SentiSense, with up to forty quarters and twenty fiscal years of history.